United Therapeutics (UTHR)

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Company profile

Ticker

UTHR

Exchange

NASDAQ

Website

www.unither.com

CEO

Martine Rothblatt

Incorporated

Delaware

Location

Maryland

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie ...

SEC CIK

0001082554

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Lung Bioengineering Inc. • Lung Biotechnology PBC, a Delaware public benefit corporation • Revivicor, Inc. • United Therapeutics Europe, Ltd., a company incorporated • Unither Biotech Inc. • Unither Bioelectronics, Inc. • Unither Pharma, LLC • Unither Pharmaceuticals, LLC • Unither Telmed, Ltd. • Unither Therapeutik GmbH ...

IRS number

521984749

UTHR stock data

1M 1Y 5Y

News

From Benzinga Pro

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints

4 May 22

Here's a roundup of top developments in the biotech space over the last 24 hours.

Recap: United Therapeutics Q1 Earnings

4 May 22

United Therapeutics (NASDAQ:UTHR) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

United Therapeutics Q1 EPS $5.03 Beats $3.34 Estimate, Sales $461.90M Beat $420.02M Estimate

4 May 22

United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $5.03 per share which beat the analyst consensus estimate of $3.34 by 50.6 percent. This is a 44.13 percent increase over earnings of $3.49 per share from

Earnings Scheduled For May 4, 2022

4 May 22

Earnings Outlook For United Therapeutics

3 May 22

Press releases

From Benzinga Pro

United Therapeutics Corporation Reports First Quarter 2022 Financial Results

4 May 22

United Therapeutics Corporation (NASDAQ:UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2022. Total revenue in the first quarter of 2022 grew 22% year-over-year

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference

29 Apr 22

Mini-symposia to focus on long-term extension data for the Tyvaso® INCREASE study, the ralinepag phase 2 study, and the Orenitram® FREEDOM-EV study Poster presentations touch on real-world treprostinil use,

United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022

27 Apr 22

United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will report its first quarter 2022 financial results before the market opens on Wednesday, May 4, 2022. United Therapeutics will host a public

United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation

6 Apr 22

United Therapeutics Corporation to Present at the Oppenheimer 32nd Annual Healthcare Conference

8 Mar 22

Analyst ratings and price targets

Last 3 months

Average target

$220.67

Low target

$203.00

High target

$236.00

Calendar

4 May 22

17 May 22

31 Dec 22

Financial summary

Financial statements Chart UTHR financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	813.3M	813.3M	813.3M	813.3M	813.3M	813.3M
Cash burn (monthly)	27.17M	1.58M	(no burn)	(no burn)	(no burn)	(no burn)
Cash used (since last report)	42.24M	2.46M	n/a	n/a	n/a	n/a
Cash remaining	771.06M	810.84M	n/a	n/a	n/a	n/a
Runway (months of cash)	28.4	512.1	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

UTHR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 May 22	Dwek Raymond	Common Stock	Sale back to company	Dispose D	No	Yes	186.99	2,000	373.98K	0
5 May 22	Dwek Raymond	Common Stock	Option exercise	Acquire M	No	Yes	48.11	2,000	96.22K	2,000
5 May 22	Dwek Raymond	Share Tracking Award Common Stock	Option exercise	Dispose M	No	Yes	48.11	2,000	96.22K	0
5 May 22	Mahon Paul A	Common Stock	Sell	Dispose S	No	Yes	192.9221	700	135.05K	36,397
5 May 22	Mahon Paul A	Common Stock	Sell	Dispose S	No	Yes	191.7233	900	172.55K	37,097
5 May 22	Mahon Paul A	Common Stock	Sell	Dispose S	No	Yes	190.3573	3,100	590.11K	37,997
5 May 22	Mahon Paul A	Common Stock	Sell	Dispose S	No	Yes	189.3765	1,300	246.19K	41,097
5 May 22	Mahon Paul A	Common Stock	Option exercise	Acquire M	No	Yes	111	6,000	666K	42,397
5 May 22	Mahon Paul A	Stock Options Common Stock	Option exercise	Dispose M	No	Yes	111	6,000	666K	34,552
28 Apr 22	Dwek Raymond	Common Stock	Sale back to company	Dispose D	No	Yes	179.34	2,000	358.68K	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q4 2021

UTHR institutional ownership history Ownership history

93.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	405	407	-0.5%
Opened positions	54	52	+3.8%
Closed positions	56	34	+64.7%
Increased positions	134	149	-10.1%
Reduced positions	155	143	+8.4%

13F shares	Current	Prev Q	Change
Total value	9.18B	7.96B	+15.4%
Total shares	42.51M	43.09M	-1.4%
Total puts	86.8K	333.51K	-74.0%
Total calls	183.1K	230.18K	-20.5%
Total put/call ratio	0.5	1.4	-67.3%

Largest owners	Shares	Value	Change
BLK Blackrock	4.24M	$916M	-1.5%
Vanguard	4.16M	$899.1M	+0.0%
Avoro Capital Advisors	3.04M	$655.8M	+1.2%
Renaissance Technologies	2.92M	$630.35M	-3.7%
FMR	2.52M	$545.25M	+8.6%
STT State Street	1.52M	$327.85M	+3.7%
BK Bank Of New York Mellon	1.01M	$219.1M	+20.0%
Wellington Management	964.75K	$208.46M	+36863.4%
Geode Capital Management	760.95K	$164.43M	+9.0%
Fuller & Thaler Asset Management	731.39K	$158.04M	+4.2%

Largest transactions	Shares	Bought/sold	Change
Wellington Management	964.75K	+962.14K	+36863.4%
DB Deutsche Bank AG - Registered Shares	20.52K	-822.91K	-97.6%
BMO Bank of Montreal	73.53K	-524.09K	-87.7%
Polar Capital	525.67K	+432.21K	+462.5%
Norges Bank	431.9K	+431.9K	NEW
Allspring Global Investments	358.54K	+358.54K	NEW
WFC Wells Fargo & Co.	81.93K	-350.17K	-81.0%
Acadian Asset Management	346.7K	-332.4K	-48.9%
Farallon Capital Management	320.76K	+320.76K	NEW
Pictet Asset Management	538.77K	+253.35K	+88.8%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Pfizer • Vivus • Gilead Sciences • Actavis • Mannkind • FibroGen • Elbit Imaging • Arena Pharmaceuticals • Cumberland Pharmaceuticals • Insmed

Management Discussion

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
•The outcome of pending and potential future legal and regulatory actions by the U.S. Food and Drug Administration (FDA) and other regulatory and government enforcement agencies, and the anticipated duration of regulatory exclusivity for our products;
•The timing and outcome of ongoing litigation, including the lawsuit filed against us by Sandoz, Inc. (Sandoz) and Liquidia PAH, LLC (formerly known as RareGen, LLC) (RareGen); the lawsuit filed against us by MSP Recovery; our patent and trade secret litigation with Liquidia Technologies, Inc. (Liquidia) related to its NDA for Yutrepia, and with ANI Pharmaceuticals, Inc. (ANI) related to its abbreviated new drug application (ANDA) seeking FDA approval to market a generic version of Orenitram; our litigation with MSP Recovery Claims, Series LLC, and related entities; and our litigation with the U.S. Department of Health and Human Services (HHS) and the U.S. Health Resource Services Administration (HRSA) related to the Public Health Service’s 340B drug pricing program (the 340B program);

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Good

New words: Agency, aircraft, arguing, attaching, award, bioprinting, CADD, carbon, Carolina, centralized, Circuit, collateral, conflict, drone, escalation, experimental, explained, factual, feasibility, footprint, fulfill, full, gave, Heart, HSS, immunological, judge, living, magistrate, meaningful, military, moot, neighboring, nitric, North, Omicron, onset, Overnight, oxide, parent, pig, plain, plaintiff, proceed, properly, proximate, punitive, reached, repaid, rest, resumed, Robert, Roscigno, RSU, Russia, School, SOFR, stipulation, strength, suing, survived, synthase, temporary, tentative, theory, Toronto, transcend, UAB, UHeart, UKidney, Ukraine, Unitherian, Yutrepia

Removed: accessibility, accuracy, afford, amending, applied, ASP, ASU, authority, benchmark, biocompatibility, busy, cassette, chemistry, clarification, CMC, commitment, compelling, concomitant, confident, conform, considerable, consistency, consulting, contracting, cope, daily, diagnostic, distancing, donor, earliest, economy, effected, Emerging, emphysema, England, equipped, Europe, exist, expert, extremely, Facilitation, fact, FASB, feedback, fiscal, free, GAAP, hedging, identifying, immaterial, implantable, institution, issuing, Joint, lessen, LIBOR, measuring, Medtronic, municipality, optional, OreniPro, participant, pertaining, PMA, premarket, preventative, printing, prioritization, rapidly, rating, reclassified, recommended, recruit, redesign, redesigned, RemoLife, remotely, removing, repayment, responding, secondary, select, serve, Simplifying, spending, staffing, stage, standard, SteadyMed, stop, supplement, Task, Topic, training, transition, unit, utilizing, virtual, visibility, voluntary

From filing 10-Q 2022 Q1

Financial reports

View all